| 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative D Aletaha, T Neogi, AJ Silman, J Funovits, DT Felson, CO Bingham III, ... Arthritis & rheumatism 62 (9), 2569-2581, 2010 | 14775 | 2010 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update JS Smolen, R Landewé, J Bijlsma, G Burmester, K Chatzidionysiou, ... Annals of the rheumatic diseases 76 (6), 960-977, 2017 | 3120 | 2017 |
| Treating rheumatoid arthritis to target: recommendations of an international task force JS Smolen, D Aletaha, JWJ Bijlsma, FC Breedveld, D Boumpas, ... Annals of the rheumatic diseases 69 (4), 631-637, 2010 | 2912 | 2010 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update JS Smolen, R Landewé, FC Breedveld, M Buch, G Burmester, ... Annals of the rheumatic diseases 73 (3), 492-509, 2014 | 2889 | 2014 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs JS Smolen, R Landewé, FC Breedveld, M Dougados, P Emery, ... Annals of the rheumatic diseases 69 (6), 964-975, 2010 | 2393 | 2010 |
| American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials DT Felson, JS Smolen, G Wells, B Zhang, LHD Van Tuyl, J Funovits, ... Arthritis & Rheumatism 63 (3), 573-586, 2011 | 1879 | 2011 |
| EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics … B Combe, R Landewé, C Lukas, HD Bolosiu, F Breedveld, M Dougados, ... Annals of the rheumatic diseases 66 (1), 34-45, 2007 | 1189 | 2007 |
| Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty‐two–week, phase III … E Keystone, DVD Heijde, D Mason Jr, R Landewé, RV Vollenhoven, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2008 | 794 | 2008 |
| Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study A Naranjo, T Sokka, MA Descalzo, J Calvo-Alén, K Hørslev-Petersen, ... Arthritis research & therapy 10, 1-10, 2008 | 717 | 2008 |
| Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage O Meyer, C Labarre, M Dougados, P Goupille, A Cantagrel, A Dubois, ... Annals of the rheumatic diseases 62 (2), 120-126, 2003 | 678 | 2003 |
| 2016 update of the EULAR recommendations for the management of early arthritis B Combe, R Landewe, CI Daien, C Hua, D Aletaha, JM Álvaro-Gracia, ... Annals of the rheumatic diseases 76 (6), 948-959, 2017 | 665 | 2017 |
| Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force JS Smolen, J Braun, M Dougados, P Emery, O FitzGerald, P Helliwell, ... Annals of the rheumatic diseases 73 (1), 6-16, 2014 | 619 | 2014 |
| Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS) X Mariette, P Ravaud, S Steinfeld, G Baron, J Goetz, E Hachulla, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2004 | 551 | 2004 |
| Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis MH Buch, JS Smolen, N Betteridge, FC Breedveld, G Burmester, T Dörner, ... Annals of the rheumatic diseases 70 (6), 909-920, 2011 | 520 | 2011 |
| Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases JE Gottenberg, L Guillevin, O Lambotte, B Combe, Y Allanore, ... Annals of the rheumatic diseases 64 (6), 913-920, 2005 | 511 | 2005 |
| Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs … M Weinblatt, B Combe, A Covucci, R Aranda, JC Becker, E Keystone Arthritis & Rheumatism 54 (9), 2807-2816, 2006 | 497 | 2006 |
| Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations D Aletaha, R Landewe, T Karonitsch, J Bathon, M Boers, C Bombardier, ... Arthritis Care & Research: Official Journal of the American College of …, 2008 | 488 | 2008 |
| Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry B Terrier, Z Amoura, P Ravaud, E Hachulla, R Jouenne, B Combe, ... Arthritis & Rheumatism 62 (8), 2458-2466, 2010 | 459 | 2010 |
| Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised … P Nash, B Kirkham, M Okada, P Rahman, B Combe, GR Burmester, ... The Lancet 389 (10086), 2317-2327, 2017 | 446 | 2017 |
| Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind … MC Genovese, R Fleischmann, B Combe, S Hall, A Rubbert-Roth, ... The Lancet 391 (10139), 2513-2524, 2018 | 445 | 2018 |
